7 Recruiting Malignant Solid Neoplasm Phase 2 Clinical Trials
Active phase 2 studies for malignant solid neoplasm enrolling across the USA. Verify eligibility and contact site coordinators.
All Malignant Solid Neoplasm studiesPhase 2 Studies for Malignant Solid Neoplasm
🔵 Active, Not Recruiting Phase2
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
📍 Children's Hospital of Alabama — Birmingham, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
📍 National Cancer Institute Developmental Therapeutics Clinic — Bethesda, Maryland
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2
Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
📍 Roswell Park Cancer Institute — Buffalo, New York
View Study & Checklist ➔